Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex

This study has been completed.
Information provided by (Responsible Party):
GW Pharmaceuticals Ltd. Identifier:
First received: March 23, 2011
Last updated: June 13, 2013
Last verified: June 2013